Update on E. coli Vaccine Development by Sanofi
The ongoing pursuit of a vaccine for extraintestinal pathogenic E. coli by Sanofi has reached a significant milestone, but not without challenges. An independent interim analysis of the E.mbrace phase 3 study indicated that the vaccine did not meet the necessary efficacy benchmarks for preventing invasive E. coli diseases. While the study results were disappointing, they shed light on the complexities of vaccine development in this area.
Details from the E.mbrace Phase 3 Study
The independent data monitoring committee (IDMC) assessed the vaccine candidate's effectiveness compared with a placebo and found it lacking. Fortunately, throughout the study's course, no safety concerns related to the vaccine candidate were reported. This thorough approach not only underscores the commitment to participant safety but also highlights the importance of immediate treatment for any incidences of invasive E. coli disease among trial participants.
Sanofi’s Strategic Approach
Jean-François Toussaint, the Global Head of Research and Development for Vaccines at Sanofi, expressed disappointment regarding the trial's outcome. He emphasized the urgency of addressing E. coli sepsis, a severe condition with currently no preventive measures. Toussaint assured that the dedicated team would delve into the factors influencing the IDMC's decision and will share further insights as they become available.
Collaboration with Janssen Pharmaceuticals
In a landmark agreement signed in October 2023, Sanofi partnered with Janssen Pharmaceuticals Inc. (a subsidiary of Johnson & Johnson), to oversee the development and commercialization of this vaccine candidate. Both corporations committed to sharing research and development costs, with an upfront payment of $250 million, which was intended to cover developmental milestones and future commercialization efforts.
Study Background and Participant Overview
The E.mbrace study, a randomized, double-blind, placebo-controlled trial, was designed to evaluate the efficacy, safety, and immunogenicity of a single dose of the vaccine candidate in preventing invasive E. coli disease, including conditions such as sepsis and bacteremia. Commencing in June 2021, the trial enrolled adults aged 60 and older with historically stable health and prior urinary tract infections, conducted at over 250 locations globally.
Financial Implications of the Study's Discontinuation
Following the decision to discontinue the study, Sanofi was required to report a pre-tax impairment charge of $250 million in its financial records for Q4 2024. This adjustment has now adjusted the forecasted earnings per share to €4.44, down from €4.59. However, it is important to note that this does not affect the overall business net income or business EPS, which remain unchanged. Sanofi maintains its financial predictions for the upcoming year without alteration.
About Sanofi's Mission
Sanofi is committed to healthcare innovation, propelling forward with the aim of enhancing medical practices through scientific advancements. The global team at Sanofi is devoted to transforming lives by providing groundbreaking treatments and vaccines to millions, while prioritizing sustainability and social responsibility in all initiatives.
Company Information and Contacts
Sanofi, publicly traded on EURONEXT: SAN and NASDAQ: SNY, invites media inquiries for more information.
Media Relations Contacts:
Sandrine Guendoul | +33 6 25 09 14 25
Evan Berland | +1 215 432 0234
Nicolas Obrist | +33 6 77 21 27 55
Léo Le Bourhis | +33 6 75 06 43 81
Victor Rouault | +33 6 70 93 71 40
Timothy Gilbert | +1 516 521 2929
Investor Relations Contacts:
Thomas Kudsk Larsen | +44 7545 513 693
Alizé Kaisserian | +33 6 47 04 12 11
Felix Lauscher | +1 908 612 7239
Keita Browne | +1 781 249 1766
Nathalie Pham | +33 7 85 93 30 17
Tarik Elgoutni | +1 617 710 3587
Thibaud Châtelet | +33 6 80 80 89 90
Frequently Asked Questions
What was the outcome of the E.mbrace phase 3 study?
The study concluded that the vaccine candidate did not demonstrate sufficient efficacy in preventing invasive E. coli disease compared to placebo.
Are there any safety concerns regarding the vaccine candidate?
No safety signals related to the vaccine candidate were reported throughout the study.
Who conducted the independent analysis for the study?
An independent data monitoring committee (IDMC) was responsible for the interim analysis of the study's results.
What is Sanofi's commitment moving forward?
Sanofi remains dedicated to driving innovation in vaccine R&D and will continue to explore further insights regarding the trial's findings.
What financial impact did the study discontinuation have on Sanofi?
Sanofi reported a pre-tax impairment charge of $250 million but maintained its net income and EPS predictions for the upcoming year.
